Esperion Theraptc (ESPR) Stock Price, Quote & News

Company Profile

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 734 887 3903

Website: www.esperion.com

Address:

3891 Ranchero Drive, Suite 150, Ann Arbor, United States

biotech_expert Apr. 5 at 3:05 AM

$ESPR If Sheldon was smart, he'd walk over to Crisler and ask Dusty May to speak to his sales staff to motivate them to sell BA. Dusty knows how to get his guys cooking!

0 · Reply

Gary9912 Apr. 4 at 11:52 PM

$ESPR Canada launch appears to be underway. Please keep this quiet so Sheldon doesn’t find out. I’m suspcting that as soon as he realizes that there are royalties coming in from Canada he will find a way to trade them away for some tiny company. 😂

1 · Reply

bportan1 Apr. 4 at 10:26 PM

$ESPR @Shar1ah would love to see your imagined SEC complaint: “I invested in a company and I’m extremely stupid so I didn’t understand the legal separation of management and control. So when management made a decision I disagreed with, I felt criminally victimized because I’m a giant fucking moron. I would like my money back and I’m writing to you because that’s what I think the SEC does: mediate disputes between ownership and management about tactical business decisions. Best, Almost impossibly ignorant forum weirdo.

1 · Reply

Lskynrd1 Apr. 4 at 12:51 PM

$ESPR Retail sentiment is low right now can't blame us, but the science case for BA is still intact. A big question now for me is who eventually unlocks the value. Current management, activist investors or a buyer at some point. Bio history tells us when a great drug sits in a poorly valued company eventually some1 will step in. Keepin the faith ✊👏💰

2 · Reply

Shar1ah Apr. 4 at 9:58 AM

$ESPR Write to Sec if you don't want these swings for 5 years. You are being robbed ))

0 · Reply

Deliver1 Apr. 4 at 4:46 AM

$ESPR Article of interest: ( not just for congestive heart failure) Excerpt 1 ...an outpatient diuretic therapy indicated for the treatment of adults with edema associated with congestive heart failure, liver disease, and kidney disease, including nephrotic syndrome, according to a news release from Corstasis Therapeutics. https://www.pharmacytimes.com/view/fda-approves-bumetanide-nasal-spray-for-edema-with-heart-failure-hepatic-and-renal-disease

1 · Reply

Enjoyycall Apr. 4 at 4:38 AM

$ESPR Market was closed today, folks 😂 Touch some grass unless you’re chasing that post cash.

1 · Reply

omar_progressivetrading Apr. 4 at 2:35 AM

$ESPR — What a day for the books! To The Moon & Beyond! 🫡 🌓

1 · Reply

meistermell Apr. 4 at 1:17 AM

$ESPR partnering early would have been a grave mistake, shutting down peak revenues for many years at the mimimum from 2030-2035, most likely to 2040 and beyond. And it wouldn't have prevented cash raises and share offerings as upfront money is maybe 50MM so early on (no guidelines, label expansion) if you're lucky and you're stuck with max double digit royalties for the rest of the drugs ascend. What they have been doing for the past 2-3 years tracks well and makes sense.

0 · Reply

wRsYUeX Apr. 4 at 12:55 AM

$ESPR what we do know is that if you can’t sell your own drug, you certainly cannot expect to sell someone else’s drug. Sheldung should have partnered US rights several years ago!!!

0 · Reply

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

Apr 2, 2026, 4:00 PM EDT - 2 days ago

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Mar 16, 2026, 6:30 AM EDT - 19 days ago

Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

Mar 10, 2026, 10:40 AM EDT - 25 days ago

Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript

Mar 10, 2026, 6:00 AM EDT - 25 days ago

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 3, 2026, 5:22 PM EST - 4 weeks ago

Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript

Mar 3, 2026, 6:00 AM EST - 4 weeks ago

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Feb 18, 2026, 8:00 AM EST - 6 weeks ago

Esperion to Participate in The 2026 Citizens Life Sciences Conference

Feb 17, 2026, 8:00 AM EST - 6 weeks ago

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Feb 11, 2026, 4:30 PM EST - 7 weeks ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 14, 2026, 7:35 PM EST - 2 months ago

Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 6:00 PM EST - 2 months ago

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Nov 20, 2025, 4:03 PM EST - 4 months ago

Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 7:00 AM EST - 4 months ago

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Nov 12, 2025, 10:16 AM EST - 5 months ago

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

CCCC CWST INSP MNDY SITM

Nov 11, 2025, 9:31 PM EST - 5 months ago

Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript

Nov 10, 2025, 7:24 AM EST - 5 months ago

Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability

Nov 6, 2025, 2:06 PM EST - 5 months ago

Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 8:00 AM EST - 5 months ago

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Oct 27, 2025, 8:00 AM EDT - 5 months ago

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Oct 8, 2025, 8:01 AM EDT - 6 months ago

Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

JOBY PENG

Oct 7, 2025, 9:29 PM EDT - 6 months ago

Esperion Announces Pricing of Public Offering of Common Stock

Oct 7, 2025, 4:01 PM EDT - 6 months ago

Esperion Announces Proposed Public Offering of Common Stock

Oct 3, 2025, 8:00 AM EDT - 6 months ago

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

Sep 19, 2025, 8:00 AM EDT - 7 months ago

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Sep 7, 2025, 10:17 PM EDT - 7 months ago

Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 10:39 AM EDT - 7 months ago

Top 2 Health Care Stocks That May Plunge This Month

NUVB

Aug 29, 2025, 8:00 AM EDT - 7 months ago

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Aug 5, 2025, 10:10 AM EDT - 8 months ago

Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 6:00 AM EDT - 8 months ago

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 22, 2025, 8:00 AM EDT - 9 months ago

Esperion to Report Second Quarter 2025 Financial Results on August 5

Jul 1, 2025, 8:06 AM EDT - 9 months ago

Esperion Appoints Craig Thompson to Board of Directors

Jun 14, 2025, 7:03 AM EDT - 10 months ago

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?

May 12, 2025, 8:00 AM EDT - 11 months ago

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

May 9, 2025, 8:00 AM EDT - 11 months ago

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

May 8, 2025, 6:30 AM EDT - 11 months ago

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

May 6, 2025, 10:49 AM EDT - 11 months ago

Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Esperion to Participate in The Citizens Life Sciences Conference

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Esperion Appoints Robert E. Hoffman to Board of Directors

Mar 4, 2025, 10:34 AM EST - 1 year ago

Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 6:00 AM EST - 1 year ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Feb 18, 2025, 8:00 AM EST - 1 year ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Dec 18, 2024, 7:00 AM EST - 1 year ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Dec 14, 2024, 9:00 AM EST - 1 year ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

CRDF UI VOD DE FLNC GASS HII

Dec 13, 2024, 6:00 AM EST - 1 year ago

Esperion Announces $210 Million Convertible Debt Financing

Dec 12, 2024, 8:00 AM EST - 1 year ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Dec 8, 2024, 7:43 AM EST - 1 year ago

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

biotech_expert Apr. 5 at 3:05 AM

$ESPR If Sheldon was smart, he'd walk over to Crisler and ask Dusty May to speak to his sales staff to motivate them to sell BA. Dusty knows how to get his guys cooking!

0 · Reply

Gary9912 Apr. 4 at 11:52 PM

1 · Reply

bportan1 Apr. 4 at 10:26 PM

1 · Reply

Lskynrd1 Apr. 4 at 12:51 PM

2 · Reply

Shar1ah Apr. 4 at 9:58 AM

$ESPR Write to Sec if you don't want these swings for 5 years. You are being robbed ))

0 · Reply

Deliver1 Apr. 4 at 4:46 AM

1 · Reply

Enjoyycall Apr. 4 at 4:38 AM

$ESPR Market was closed today, folks 😂 Touch some grass unless you’re chasing that post cash.

1 · Reply

omar_progressivetrading Apr. 4 at 2:35 AM

$ESPR — What a day for the books! To The Moon & Beyond! 🫡 🌓

1 · Reply

meistermell Apr. 4 at 1:17 AM

0 · Reply

wRsYUeX Apr. 4 at 12:55 AM

$ESPR what we do know is that if you can’t sell your own drug, you certainly cannot expect to sell someone else’s drug. Sheldung should have partnered US rights several years ago!!!

0 · Reply

Albertwest Apr. 3 at 11:48 PM

$ESPR I know many here wish they had cashed out at $4, or were expecting to see $5 or $6 by now after years on this roller coaster board/stock. To be fair, management did diversify the product portfolio by acquiring an approved and already commercialized drug. Was it the right move? Idk but relying 100% on a single product is always a risk, so some diversification makes sense. Will Enbumyst be a blockbuster? It doesn’t seem likely but IMO it will contribute more to the bottom line than the Japan royalties would have. On the financing side, was it the best decision? Again, unclear but what concerns me the most is the additional $25 million added to the Athyrium Capital Management loan from December 2024. It carries a 9.75% interest rate and begins amortizing at 12.5% per quarter starting in Q4 2028. We need strong US sales ASAP, Japan royalties were never going to cover Esperion’s financial gap.

1 · Reply

YoloAlfred Apr. 3 at 11:13 PM

$ESPR Look Dad...Gregg Gary and I had a family meeting and you promised you would not create another personality. Mom left you over this very thing when we were young children. I know you didn't like Napa State Hospital but Im affraid it might be a good idea to get some help. And most of all we explained this person DJ never existed...he was a made up personality you created to get over being touched.🤝🤷‍♂️🤦‍♂️❤️🫂

1 · Reply

OldManLogan Apr. 3 at 10:29 PM

$ESPR No offense, but the guy's not here to defend himself but if he was, I'm sure he'd say that he gets a kick out of the fact that he still lives "rent free" in your head, even though he hasn't posted in months. My guess is that switch gets flipped once there is clarity on patent defense wrt the ANDA filers.

4 · Reply

Korazov Apr. 3 at 9:01 PM

$ESPR only stupid losers can say so about man who cant answer to him and dont post here for month, but dumbass losers cant forgot him

1 · Reply

meistermell Apr. 3 at 8:45 PM

$ESPR Nexlizet approval and and launch milestone payments could cover up to half of the money owed to Athyrium, we estimate $20MM-$50MM. 5 years tops, we estimate 4 conservatively.

1 · Reply

meistermell Apr. 3 at 8:28 PM

$ESPR he wasn't wrong there at the higher tiers. He could have also included milestones. He may have been overly optimistic, but closer than the calculation below which completely ignores 2 years of shutdown at launch, as well as updated guidelines only after 5 years in and different poulation characteristics, such as much higher statin intolerance in Japan.

1 · Reply

Phasedrei Apr. 3 at 8:27 PM

$ESPR So far, Japan has only launched Nexletol. Nexlizet will be launched later, likely not until late 2026 or even 2027. I don’t know the sales figures for other EU countries, but in Germany—the largest market—Nustendi (Nexlizet) now accounts for approximately 80% of sales. Nilemdo and Nustendi are priced the same there on an N1 basis, and there is no Nilemdo N3 package. Therefore, I’m also estimating a timeframe of 6–7 years, unless the upcoming Nexlizet launch in Japan triggers a milestone payment.

0 · Reply

In_Harlow_We_Trust Apr. 3 at 8:04 PM

$ESPR Remember Dumbass DJ’s overly optimistic spreadsheet stating Otsuka royalties would be $100M in just a couple years. Cause all they needed to do was flip a switch. Many on this board worshipped an idiot (or a conman).

1 · Reply

meistermell Apr. 3 at 7:54 PM

$ESPR Furthermore all royalties incl. milestone payments (450MM pool) will go to Athyrium first, Gemini is even more optimistic and assumes late 2020s as reversal for the Japan revenue stream back to the company. Make that 2029, 4 years

0 · Reply

BioBum Apr. 3 at 7:42 PM

$ESPR Im not concerned about Bumetanide spray and its abilities to help patients and be effective in certain situations. I’m SUPER concerned that you have another “not first line” and “saturated with generics” drug you have to market. It would’ve one thing if nex USA sales were GREAT. But, they aren’t. If you can’t kill the script counts with bempedoic acid, how the HELL do you penetrate the diuretic market riddled by generics. If I picked 10 docs right now and told them about the spray, they would all pick increasing current diuretics for their patients. This will require an enormous amount of education and a paradigm shift. How do reps do that?

1 · Reply

meistermell Apr. 3 at 7:40 PM

$ESPR 12% is the low end royalty rate. European guidelines were just updated 2H25, and when they launched the first 2 years they were shut down by the covid cold plandemic, effectively reducing the launch to 3 years. Japan's population is quite more sensitive to even low dosages of statins and has a high complete statin intolerance rate. BA will be the go to drug for all of those patients, it's priced .lmodesty like most drugs and will replace statins outside of TC. 5 years max.

0 · Reply

Dave_100 Apr. 3 at 7:15 PM

$ESPR DSE has yet to hit the threshold that increases the royalty from the minimum of 15%. In the five years they have been selling they have sold roughly $750M cumulatively. If we get 12% of Otsuka sales then that requires $833M in sales cumulatively to pay back $100M. So for pay back in less than 6 years we have to assume Otsuka sells more/faster than DSE did in all of Europe. It’s possible but I would not say likely.

0 · Reply

Market Cap	670.27M
Revenue (ttm)	403.14M
Net Income (ttm)	-22.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	56.74
Profit Margin	-5.63%
Debt to Equity Ratio	-0.50

Volume	5,845,300
Avg Vol	4,732,124
Day's Range	N/A - N/A
Shares Out	256.81M
Stochastic %K	32%
Beta	1.17
Analysts	Sell
Price Target	$6.97